Notably, BRAF mutations, which are common in CRC, have been shown to confer resistance to RAF inhibitors, such as vemurafenib, due to reactivation of the MAPK pathway through EGFR signaling [19,20]. This evidence concerns the gene EGFR and colorectal carcinoma.